Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus MD 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus MD 50.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs MD-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
300 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent